The Developmental Funds at this CCSG are also used to fund pilot projects in new research directions. The ability to provide funding for pilot projects is a highly effective mechanism for the Director and Program Leaders to influence the progress of cancer research at MIT and to rapidly respond to new opportunities and new strategic directions. It also represents a means to bring different Kl members together in collaborative projects. Pilot projects are expected to be novel and eariy-stage. They are often high risk/high reward in nature, and it is anticipated that the funding will allow for the generation of preliminary data that might form the basis of future grant applications. During the past grant period, eight pilot projects were selected for funding. Funds were awarded to projects in years 32, 34 and 37. Due to budget reductions in the CCSG, we were able to support fewer pilot projects than originally planned. However, as described below, projects that were funded have led to a series of very interesting observations, several publications and some new grant applications. In the current application, we are seeking funds sufficient to support 3 pilot projects annually. As is currentiy the case, applications will be reviewed by the Kl Director and a committee of faculty and awarded on the basis of both the quality of the application and on the novelty of the approaches proposed. Program leaders are encouraged to stimulate new directions of research within their Programs by encouraging their members to apply for pilot project funding;they also help to organize intra- and inter-programmatic collaborations. As has been true in the past, we anticipate that this mechanism will be very effective in assisting Kl members to embark on innovative research projects with potential for a significant impact on cancer diagnosis, treatment and control. With the introduction of the Koch Clinical Investigators Program as well as increased interactions with local clinical centers, there is an increased opportunity for clinically-oriented pilot projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014051-42
Application #
8466724
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
42
Fiscal Year
2013
Total Cost
$198,841
Indirect Cost
$88,839
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Tentori, Augusto M; Nagarajan, Maxwell B; Kim, Jae Jung et al. (2018) Quantitative and multiplex microRNA assays from unprocessed cells in isolated nanoliter well arrays. Lab Chip 18:2410-2424
Parisi, Tiziana; Balsamo, Michele; Gertler, Frank et al. (2018) The Rb tumor suppressor regulates epithelial cell migration and polarity. Mol Carcinog 57:1640-1650
Gam, Jeremy J; Babb, Jonathan; Weiss, Ron (2018) A mixed antagonistic/synergistic miRNA repression model enables accurate predictions of multi-input miRNA sensor activity. Nat Commun 9:2430
Chen, Huihui; Cho, Kin-Sang; Vu, T H Khanh et al. (2018) Commensal microflora-induced T cell responses mediate progressive neurodegeneration in glaucoma. Nat Commun 9:3209
Tam, Brooke E; Hao, Yining; Sikes, Hadley D (2018) An examination of critical parameters in hybridization-based epigenotyping using magnetic microparticles. Biotechnol Prog 34:1589-1595
Ramadi, Khalil B; Dagdeviren, Canan; Spencer, Kevin C et al. (2018) Focal, remote-controlled, chronic chemical modulation of brain microstructures. Proc Natl Acad Sci U S A 115:7254-7259
Knouse, Kristin A; Lopez, Kristina E; Bachofner, Marc et al. (2018) Chromosome Segregation Fidelity in Epithelia Requires Tissue Architecture. Cell 175:200-211.e13
Sabari, Benjamin R; Dall'Agnese, Alessandra; Boija, Ann et al. (2018) Coactivator condensation at super-enhancers links phase separation and gene control. Science 361:
Fiedler, Eleanor R C; Bhutkar, Arjun; Lawler, Emily et al. (2018) In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1 + BCP-ALL. Blood Adv 2:1229-1242
Clancy-Thompson, Eleanor; Devlin, Christine A; Tyler, Paul M et al. (2018) Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8+ T Cell-Effector Responses. Cancer Immunol Res 6:1524-1536

Showing the most recent 10 out of 904 publications